Business Description
ARS Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US82835W1080
Total Employee Number:
159Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.08 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 1.57 | |||||
Debt-to-EBITDA | -0.51 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.7 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 195.9 | |||||
3-Year EBITDA Growth Rate | -24.8 | |||||
3-Year EPS without NRI Growth Rate | -26.2 | |||||
3-Year FCF Growth Rate | -19.9 | |||||
3-Year Book Growth Rate | -26.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 69.21 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 72.74 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.56 | |||||
9-Day RSI | 35.93 | |||||
14-Day RSI | 40.83 | |||||
3-1 Month Momentum % | 12.95 | |||||
6-1 Month Momentum % | -22.15 | |||||
12-1 Month Momentum % | -48.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.94 | |||||
Quick Ratio | 4.77 | |||||
Cash Ratio | 4.05 | |||||
Days Inventory | 116.78 | |||||
Days Sales Outstanding | 92.1 | |||||
Days Payable | 109.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -9.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.12 | |||||
Operating Margin % | -204.49 | |||||
Net Margin % | -200 | |||||
EBITDA Margin % | -191.72 | |||||
FCF Margin % | -177.11 | |||||
OCF Margin % | -176.86 | |||||
ROE % | -132.96 | |||||
ROA % | -60.77 | |||||
ROIC % | -516.66 | |||||
3-Year ROIIC % | -359.4 | |||||
ROC (Joel Greenblatt) % | -7941.21 | |||||
ROCE % | -67.01 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.9 | |||||
PB Ratio | 12.81 | |||||
Price-to-Tangible-Book | 16.54 | |||||
EV-to-EBIT | -3.6 | |||||
EV-to-Forward-EBIT | 56.21 | |||||
EV-to-EBITDA | -3.6 | |||||
EV-to-Revenue | 6.91 | |||||
EV-to-Forward-Revenue | 5.15 | |||||
EV-to-FCF | -3.9 | |||||
| Price-to-Net-Current-Asset-Value | 41.79 | |||||
Earnings Yield (Greenblatt) % | -27.78 | |||||
FCF Yield % | -22.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARS Pharmaceuticals Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 98.986 | ||
| EPS (TTM) ($) | -2.01 | ||
| Beta | 2.0443 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 50.71 | ||
| 14-Day RSI | 40.83 | ||
| 14-Day ATR ($) | 0.761029 | ||
| 20-Day SMA ($) | 9.2645 | ||
| 12-1 Month Momentum % | -48.02 | ||
| 52-Week Range ($) | 6.66 - 18.63 | ||
| Shares Outstanding (Mil) | 99.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARS Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 132 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:30 | In 44 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 43 days | ||
| General meeting for 2026 | 2026-06-24 07:30 | 10.28 (+3.68%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | 7.94 (-2.34%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 7.94 (-2.34%) | ||
| 38th Annual ROTH Conference | 2026-03-22 | 8.17 (-0.61%) | ||
| Leerink Conference | 2026-03-11 08:00 | 8.86 (-2.64%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-09 08:30 | 9.06 (+2.26%) |
Show
Entries
ARS Pharmaceuticals Inc Frequently Asked Questions
What is ARS Pharmaceuticals Inc(SPRY)'s stock price today?
The current price of SPRY is $7.94. The 52 week high of SPRY is $18.63 and 52 week low is $6.66.
When is next earnings date of ARS Pharmaceuticals Inc(SPRY)?
The next earnings date of ARS Pharmaceuticals Inc(SPRY) is 2026-08-13 Est..
Does ARS Pharmaceuticals Inc(SPRY) pay dividends? If so, how much?
ARS Pharmaceuticals Inc(SPRY) does not pay dividend.
Guru Commentaries on NAS:SPRY
No articles.
Press Release
Articles on ARS Pharmaceuticals Inc
No articles.
Headlines
See More- 1
Jun 25, 2026
ARS Pharmaceuticals plunges 23% as neffy fails to secure insurance coverage
Seeking Alpha • 4:48am
Biggest stock movers Thursday: AI chip stocks, WEN, SPRY, and more
Seeking Alpha • 4:01am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers